ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 458

November 30, 1985

CONGENITAL ADRENAL HYPERPLASIA[a]

Editor

MARIA I. NEW

Organizing Committee

M. I. NEW, B. DUPONT, G. P. CHROUSOS, and D. LORIAUX

CONTENTS

Introduction. *By* ALFRED M. BONGIOVANNI ix

Clinical and Endocrinological Aspects of 21-Hydroxylase Deficiency. *By* MARIA I. NEW 1

Extended MHC Haplotypes in Salt-Losing 21-Hydroxylase Deficiency. *By* CHESTER A. ALPER, ELLEN FLEISCHNICK, ZUHEIR AWDEH, DONALD RAUM, JOHN F. CRIGLER, JR., PARK S. GERALD, and EDMOND J. YUNIS 28

The HLA Associations in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency in a Yugoslav Population. *By* A. KAŠTELAN, LJ. BRKLJAČIĆ-ŠURKALOVIĆ, and M. DUMIĆ 36

HLA Associations in 21-Hydroxylase Deficiency (Congenital and Late-Onset Adrenal Hyperplasia) in France. *By* P. COUILLIN, R. RAPPAPORT, F. KUTTENN, J. HORS, J. FEINGOLD, J. BOUÉ, and A. BOUÉ 41

The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy. *By* SERAFINO ZAPPACOSTA, MICHELE MAIO, MARIO DE FELICE, and ROSSELLA VALENTINO 46

HLA Associations in Late-Onset 21-Hydroxylase Deficiency in Israel. *By* Z. LARON, A. ROITMAN, A. PERTZELAN, H. KAUFMAN, and R. ZAMIR 52

HLA-B14 and Nonclassical 21-Hydroxylase Deficiency in a Heterogeneous New York Population. *By* LENORE S. LEVINE 65

Different Gene Defects in the Salt-Wasting (SW), Simple Virilizing (SV), and Nonclassical (NC) Types of Congenital Adrenal Hyperplasia (CAH). *By* D. KNORR, E. D. ALBERT, F. BIDLINGMAIER, W. HÖLLER, and S. SCHOLZ.. 71

[a]The papers in this volume were presented at the Symposium on Advances in Congenital Adrenal Hyperplasia, which was held on July 7–9, 1984 in New York City as part of the Satellite Meeting of the VIIth International Congress of Endocrinology. The symposium was sponsored by the National Institute of Child Health and Human Development, the National Institutes of Health (Bethesda, Maryland 20205), and the Cornell University Medical College (New York, New York 10021). Additional support was provided by The Lindemann Foundation, Hoffmann-LaRoche Inc., Ross Laboratories, and Wyeth Laboratories.

The Coexistence of IgA Deficiency and 21-Hydroxylase Deficiency Marked by Specific MHC Supratypes. *By* T. J. COBAIN, M. S. STUCKEY, J. MCCLUSKEY, A. N. WILTON, A. GEDEON, M. J. GARLEPP, F. T. CHRISTIANSEN, and R. L. DAWKINS 76

Neonatal Screening Program for Congenital Adrenal Hyperplasia in a Homogeneous Caucasian Population. *By* E. CACCIARI, A. BALSAMO, A. CASSIO, S. PIAZZI, F. BERNARDI, S. SALARDI, A. CICOGNANI, P. PIRAZZOLI, F. ZAPPULLA, M. CAPELLI, M. PAOLINI, and C. I. CORDARO 85

Newborn Screening for Congenital Adrenal Hyperplasia with Special Reference to Screening in Alaska. *By* SONGYA PANG, DAVID A. SPENCE, and MARIA I. NEW 90

Neonatal Screening for Congenital Adrenal Hyperplasia in Japan. *By* H. NARUSE, E. SUZUKI, M. IRIE, A. TSUJI, N. TAKASUGI, M. FUKUSHI, N. MATSUURA, and K. SHIMOZAWA 103

Pitfalls of Prenatal Diagnosis of 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. *By* SONGYA PANG, MARILYN S. POLLACK, MAY LOO, ORVILLE GREEN, ROBERT NUSSBAUM, GEORGE CLAYTON, BO DUPONT, and MARIA I. NEW 111

Pitfalls in Prenatal Diagnosis of 21-Hydroxylase Deficiency by Amniotic Fluid Steroid Analysis?: A Six Years Experience in 102 Pregnancies at Risk. *By* MAGUELONE G. FOREST 130

The Use of Gamma Interferon to Increase HLA Antigen Expression on Cultured Amniotic Cells Used for the Prenatal Diagnosis of 21-Hydroxylase Deficiency. *By* DAVID H. MAURER and MARILYN S. POLLACK 148

Prenatal Therapy in Congenital Adrenal Hyperplasia: Attempted Prevention of Abnormal External Genital Masculinization by Pharmacologic Suppression of the Fetal Adrenal Gland *in Utero*. *By* GEORGE P. CHROUSOS, MARK I. EVANS, D. LYNN LORIAUX, JAMES MCCLUSKEY, JOHN C. FLETCHER, and JOSEPH D. SCHULMAN 156

Modern Medical Therapy of Congenital Adrenal Hyperplasia: A Decade of Experience. *By* JEREMY S. D. WINTER and ROBERT M. COUCH 165

LHRH Analog Treatment of Central Precocious Puberty Complicating Congenital Adrenal Hyperplasia. *By* ORA HIRSCH PESCOVITZ, FERNANDO CASSORLA, FLORENCE COMITE, D. LYNN LORIAUX, and GORDON B. CUTLER, JR. 174

Effect of Hydrocortisone Dose Schedule on Adrenal Steroid Secretion in Congenital Adrenal Hyperplasia. *By* JORG WINTERER, GEORGE P. CHROUSOS, D. LYNN LORIAUX, and GORDON B. CUTLER, JR. 182

Monitoring Treatment in Congenital Adrenal Hyperplasia: Use of Serial Measurements of 17-OH-Progesterone in Plasma, Capillary Blood, and Saliva. *By* I. A. HUGHES, J. DYAS, J. ROBINSON, R. F. WALKER, and D. R. FAHMY 193

Cytochrome P-450: Physiology of Steroidogenesis. *By* PETER F. HALL 203

Biochemical Properties of Cytochrome P-450 in Relation to Steroid Oxygenation. *By* MINOR J. COON and KUNIYO INOUYE 216

Evidence that Variation among Untreated Rabbits in Hepatic Progesterone 21-Hydroxylase Activity Is Indicative of Enzyme Heterogeneity Rather than a Transient Inductive Effect. *By* U. MULLER-EBERHARD, L. GHIZZONI, H. H. LIEM, M. NEW, M. FINLAYSON, and E. F. JOHNSON ... 225

Deoxycorticosterone Biosynthesis in Kidney Tissue of Experimental Animals: Characterization of Steroid 21-Hydroxylase Activity in Guinea Pig Kidney. *By* M. LINETTE CASEY, PAUL C. MACDONALD, and CRAIG A. WINKEL ... 232

An Approach to the Molecular Biology of Congenital Adrenal Hyperplasia. *By* BON-CHU CHUNG, KARLA J. MATTESON, JOHN E. MORIN, SYNTHIA H. MELLON, and WALTER L. MILLER ... 238

Regulation of Cytochrome P-450$_{17\alpha}$ Activity and Synthesis in Bovine Adrenocortical Cells. *By* MAURICIO X. ZUBER, EVAN R. SIMPSON, and MICHAEL R. WATERMAN ... 252

The Human Major Histocompatibility Complex: Genes and Proteins. *By* JACK L. STROMINGER ... 262

Structure Organization and Expression of the Major Histocompatibility Class III Genes. *By* HARVEY R. COLTEN ... 269

Molecular Cloning of Steroid 21-Hydroxylase. *By* PERRIN C. WHITE, MARIA I. NEW, and BO DUPONT ... 277

Index of Contributors ... 289

The New York Academy of Sciences believes it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the participants in the reported conferences are their own and not necessarily those of The Academy. The Academy has no intent to influence legislation by providing such forums.